Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

2000127 citationsJournal Articlebronze Open Access

Authors

Kazuo Nishimura · Osaka University Hospital

Norio Nonomura · The University of Osaka

Yutaka Yasunaga · The University of Osaka

Natsuki Takaha · The University of Osaka

Hitoshi Inoue · Osaka Rosai Hospital

H Sugao · Minoh City Hospital

Seiji Yamaguchi ·

Abstract

Low doses of dexamethasone were found to be beneficial in the treatment of HRPC, decreasing the severity of anemia and osseous disease as well as reducing serum PSA levels. A posttherapy serum PSA decline of > or = 50% appears to be a reliable marker of improved survival with this therapy.

Topics & Keywords

Prostate Cancer Treatment and Research Bone health and treatments Estrogen and related hormone effects

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 89, Issue 12, pp. 2570-2576

DOI: 10.1002/1097-0142(20001215)89:12<2570::aid-cncr9>3.0.co;2-h

Field-Weighted Citation Impact: 5.85